ACLX - Arcellx, Inc.
IEX Last Trade
78.69
0.020 0.025%
Share volume: 15,998
Last Updated: Fri 27 Dec 2024 08:29:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$78.67
0.02
0.03%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.90%
1 Month
-11.28%
3 Months
-4.52%
6 Months
46.01%
1 Year
37.21%
2 Year
166.78%
Key data
Stock price
$78.69
DAY RANGE
$76.13 - $79.37
52 WEEK RANGE
$50.66 - $107.37
52 WEEK CHANGE
$42.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Rami Elghandour
Region: US
Website: arcellx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arcellx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.
Recent news